Regramostim
As of the edition of 20 October 2026, Regramostim is a protein: stopped in 2025; acts on CSF3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Protein
- Registered trials
- 173, 27 stopped early
- Disease areas
- Cancer; Blood and lymph; Skin and connective tissue; Immune system; Urinary and reproductive; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 19 companies on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Regramostim.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product19 companies are on route A because of Regramostim.
See the 19 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | Q99062 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 2 | 0 | 1 |
| Phase 1 | 35 | 19 | 7 | 4 |
| Phase 2 | 113 | 53 | 15 | 22 |
| Phase 3 | 10 | 7 | 2 | 0 |
| Phase 4 | 8 | 7 | 0 | 0 |
| All trials | 173 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celldex Therapeutics | Lead sponsor of trials | 2007 to now |
| Immatics Biotechnologies | Lead sponsor of trials | 2008 to now |
| United Therapeutics | Lead sponsor of trials | 2009 to now |
| Xiamen Amoytop Biotech | Lead sponsor of trials | 2009 to now |
| Changchun GeneScience Pharmaceutical | Lead sponsor of trials | 2010 to now |
| Galena Biopharma | Lead sponsor of trials | 2011 to now |